You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》美銀證券上調石藥(01093.HK)目標價至6.5元 第三季業績受未完成藥品業務拖累
阿思達克 12-01 11:16
美銀證券發表報告指,石藥集團(01093.HK)第三季業績受未完成藥品業務拖累,收入77.85億元人民幣,按年跌1.3%,不過純利按年升1.7%至15億元人民幣。因應業績表現及減價壓力,該行將公司今年至2025年三年期間的收入預測,分別下調2.3%、1.9%及1.3%,並下調銷售成本預測、上調研發開支預測,今年每股盈利預測下調2.3%,明年及2025年分別上調0.1%及1.2%,目標價由6.31元上調至6.5元,維持其評級「跑輸大市」,主要因為競爭加劇及產品降價壓力。 管理層指,內地近日呼吸道疾病及流感個案增加,相關藥物銷售上升,另外內地早前的醫藥反貪腐令推廣活動減少,今年8月份銷售開支佔比下跌,不過相關的推廣活動在10月至11月已大致恢復,管理層預期今年收入有單位數增長,明年則加快至雙位數增長。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account